- Home
- BB vs TARS Comparison
BB vs TARS Comparison
Compare BB & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | TARS |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BB | TARS |
|---|---|---|
| Price | $4.41 | $81.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $4.98 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 6.9M | 404.5K |
| Earning Date | 12-18-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $536,600,000.00 | $366,100,000.00 |
| Revenue This Year | $2.43 | $147.24 |
| Revenue Next Year | $7.36 | $53.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 182.44 |
| 52 Week Low | $2.66 | $38.51 |
| 52 Week High | $6.24 | $85.25 |
Technical Indicators
Market Signals| Indicator | BB | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 59.46 |
| Support Level | $3.94 | $77.44 |
| Resistance Level | $4.12 | $85.25 |
| Average True Range (ATR) | 0.12 | 3.56 |
| MACD | 0.05 | -0.32 |
| Stochastic Oscillator | 93.00 | 55.84 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.